AcelRx Pharma (ACRX) to Present ARX-04 Data at ECEM 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/16/2024
- Stocks close lower as Middle East tensions, Treasury yields weigh
- Apple’s iPhone shipments dip 10% in Q1 as Samsung reclaims the top spot
- Tesla (TSLA) to cut over 10% global staff - Electrek
- Aluminum, Nickel, Copper: LME ban on Russian metal creates buying opportunity?
- Informatica (INFA) jumps as Salesforce (CRM) reportedly eyes new mega takeover
- Trump Media & Technology Group (DJT) Files S-1
- Tesla (TSLA) Senior VP Drew Baglino Is Said To Leave The Company - Bloomberg
- General Motors (GM) Said to be Moving Detroit HQ to Dan Gilbert's Hudson Tower - Bloomberg
- The Israeli Air Force Has Completed Its Preparation For An Imminent Attack Against Iran - Reuters
- Biohaven Pharma (BHVN) presents update on degrader platform and summary of progress to date in Phase 1 single ascending dose study for BHV-1300
- After-hours movers: Tesla, Gildan Activewear, Macatawa Bank, and more
- Midday movers: Goldman Sachs and Meta Platforms rise; Apple and Tesla fall
- Nike, Alpine Immune Sciences rise premarket; CarMax, Robinhood and Regeneron fall
- After-hours movers: Alpine Immune Sciences, Costco, and more
- Midday movers: Delta, Taiwan Semiconductor rise; Hexcel falls
AcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings and Cost Analysis at European Congress on Emergency Medicine
September 28, 2016 7:00 AM EDTREDWOOD CITY, Calif., Sept. 28, 2016 /PRNewswire/ --Â AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that the Company and investigators will be presenting two e-posters at the European Congress on Emergency Medicine (ECEM), which is being held October 1-5, 2016 in Vienna, Austria. Both e-posters will be displayed on monitors throughout the meeting, and will be available following the conclusion of the conference on the AcelRx... More
